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Abstract
Meridianin C is a marine natural product known for its anti‐cancer activity. At pre-
sent, the anti‐tumour effects of meridianin C on oral squamous cell carcinoma are
unknown. Here, we investigated the effect of meridianin C on the proliferation of
four different human tongue cancer cells, YD‐8, YD‐10B, YD‐38 and HSC‐3. Among
the cells tested, meridianin C most strongly reduced the growth of YD‐10B cells;
the most aggressive and tumorigenic of the cell lines tested. Strikingly, meridianin C
induced a significant accumulation of macropinosomes in the YD‐10B cells; con-
firmed by the microscopic and TEM analysis as well as the entry of FITC‐dextran,
which was sensitive to the macropinocytosis inhibitor amiloride. SEM data also
revealed abundant long and thin membrane extensions that resemble lamellipodia
on the surface of YD‐10B cells treated with meridianin C, pointing out that meridi-
anin C‐induced macropinosomes was the result of macropinocytosis. In addition,
meridianin C reduced cellular levels of Dickkopf‐related protein‐3 (DKK‐3), a known
negative regulator of macropinocytosis. A role for DKK‐3 in regulating macropinocy-
tosis in the YD‐10B cells was confirmed by siRNA knockdown of endogenous DKK‐
3, which led to a partial accumulation of vacuoles and a reduction in cell prolifera-
tion, and by exogenous DKK‐3 overexpression, which resulted in a considerable
inhibition of the meridianin C‐induced vacuole formation and decrease in cell
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survival. In summary, this is the first study reporting meridianin C has novel anti‐
proliferative effects via macropinocytosis in the highly tumorigenic YD‐10B cell line
and the effects are mediated in part through down‐regulation of DKK‐3.
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1 | INTRODUCTION
Oral squamous cell carcinoma (OSCC) is the most common malig-
nant tumour of the lip, oral cavity and oropharynx. Moreover,
OSCC can be severely disfiguring leading to a poor quality of life,
including loss of general cognitive, social, emotional or physical
functions as well as social relationships.1 The primary treatment of
OSCC is surgical removal, but radiation therapy and/or chemother-
apy have emerged as alternative treatment options for OSCC.2–4
Characteristically, OSCC cells at the late stage of malignancies are
very resistant to cancer therapy‐mediated apoptosis. Thus, there is
an urgent need for understanding resistance mechanism and identi-
fying new drugs or substances which offer therapeutic efficacy
against OSCC.
Macropinocytosis is an endocytic pathway that leads to the for-
mation of single membrane irregular vesicles (macropinosomes) by
the internalization of large patches of the plasma membrane along
with associated extracellular fluid and solutes.5 Unlike the canonical
and endocytic pathways that depend on coat proteins such as cla-
thrin or caveolin, one of the distinctive hallmarks of macropinocyto-
sis is the formation of expansive membrane ruffles within the plasma
membrane.6 This membrane ruffling is initiated by the rapid polymer-
ization of branching of actin filaments.7 Multiple proteins and sig-
nalling factors are involved in macropinocytosis, including the Rho
superfamily of GTPases (Rac, Cdc42), lipid components (phospho-
inositides, cholesterol, phosphatidylinositol phosphates), phospholipid
kinases, receptor tyrosine kinases and phosphatases, SNX‐5 and
DKK‐3.8–16 There is also large body of evidence that now shows
macropinocytosis can be specifically activated by extracellular stim-
uli, such as growth factors and natural or synthetic chemicals, and
the activated macropinocytosis can have effects on cell survival/pro-
liferation or cell death/growth inhibition on distinct cell types includ-
ing cancer cells.17,18
Meridianin C is one of the marine derived indole alkaloids
(meridianin A‐G) isolated from the South Atlantic tunicate Aplidium
meridianum.19,20 Previously, meridianin C, D or G analogues/deriva-
tives have been shown to inhibit the proliferation of human breast
(MCF‐7) and cervix (HeLa) cancer and leukaemia (MV4‐11) cells.21–
23 At present, neither the anti‐tumour effect nor the mode of
action of meridianin C in OSCC is known. In this study, we inves-
tigated the effect of meridianin C at 1 μM concentration on
growth of four different human oral carcinoma cell lines (YD‐8,
YD‐10B, YD‐38 and HSC‐3) that were originated from tongue
(YD‐8, YD‐10B, HSC‐3) or lower gingiva (YD‐38).24 It is worth
noting that YD‐8 and YD‐38 cells have no tumorigenicity, but YD‐
10B cells are highly tumorigenic and invasive/metastatic.25,26 In
this article, we report for the first time that meridianin C strongly
inhibits the growth of YD‐10B OSCC cells through macropinocyto-
sis, and its growth inhibitory and macropinocytosis inducing
effects on the cells are mediated in part via the reduced expres-
sion of DKK‐3.
2 | MATERIAL AND METHODS
2.1 | Cell culture and reagents
Four different human tongue cancer cell lines (YD‐8, YD‐10B, YD‐
38, HSC‐3) and a human bladder cancer cell line (T24) were pur-
chased from Korean Cell Line Bank (Seoul, Republic of Korea). Nor-
mal human gingival fibroblasts (HGF) were obtained from American
Type Culture Collection (ATCC, CRL‐2014™, Manassas, VA).Cells
were cultured in RPMI 1640 medium supplemented with 10%
heat‐inactivated foetal bovine serum (FBS), 100 units/mL penicillin
and 100 μg/mL streptomycin and maintained at 37°C in a humidi-
fied condition of 95% air and 5% CO2. Meridianin C was synthe-
sized as previously described 23 and prepared as a 10 mM stock
solution in DMSO. RPMI‐1640 (LM011‐01), FBS (S001‐01) and
penicillin–streptomycin (LS202‐02) were purchased from Welgene
(Deagu, Republic of Korea). All commercial antibodies and chemicals
were purchased from the following resources: anti‐procaspase‐9
(ADI‐AAM‐139) was from Enzo (Farmingdale, NY, USA); anti‐PARP
(11835238001) was from Roche Diagnostics (Mannheim, Germany);
anti‐DR5 (NBP1‐45951) was from Novus Biologicals (Littleton, CO,
USA); anti‐actin (A5441) was from Sigma (St. Louis, MO, USA);
anti‐DKK‐3 (ab187532) was from Abcam (Cambridge, MA, USA);
anti‐Flag (#2368) from Cell Signalling Technology (Danvers, MA,
USA); FITC‐dextran (average molecular weight of 70 kDa) (46945)
was from Sigma (St. Louis, MO, USA); z‐VAD‐fmk (627610) was
from Calbiochem (Madison, WI, USA); Amiloride (A7410) was from
Sigma (St. Louis, MO, USA) and protease inhibitor cocktail (PIC)
(100x) (539134) were from Calbiochem (Madison, WI, USA).
SuperSignal™ West Pico PLUS Enhanced chemiluminescence (ECL,
#34080) was purchased from Thermo Scientific (Waltham, MA,
USA). Plasticware: 6‐well plates, 24‐well plates and 60 or 100 mm
cell culture dish were purchased from SPL Life Sciences (Gyeonggi‐
do, Korea). Control siRNA (sc‐37007) and DKK‐3 siRNA (sc‐41102)
were purchased from Santa Cruz biotechnology (Delaware, CA,
USA).
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2.2 | Cell count and cell morphology analysis
Respective OSCC cell line (YD‐8, YD‐10B, YD‐38 or HSC‐3) was
seeded in 24‐well plates (1 × 105/500 μL/well) overnight. After
cells were treated with meridianin C (1 μM) or vehicle control
(DMSO; 0.1%) for 48 h, surviving cells, which cannot be stained
with trypan blue dye, were counted using phase contrast micro-
scope. Approximately 100 cells were counted for each evaluation.
The cell count assay was performed in triplicate. Data are mean ±
SEM of three independent experiments. Survival is expressed as a
percentage of control. In some experiments, YD‐10B cells
(0.5 × 106/2 mL/well) or normal HGFs‐1) (0.4 × 106/2 mL/well) were
also plated in 6‐well plates overnight. Cells were then treated with
meridianin C (1 μM) or DMSO for indicated times (YD‐10B cells
for 2, 4, 8 or 24 h; normal HGFs for 4, 8, 24 or 48 h). Phase
contrast images of the conditioned cells were taken with an
Olympus phase contrast microscope equipped with a digital
camera (Nikon).
2.3 | Transmission electron microscopy (TEM)
YD‐10B cells (0.5 × 106/2 mL/well) were seeded in 6‐well plates the
day before meridianin C treatment. Cells were then treated with
1 μM meridianin C for 8 h, while DMSO was used as control. DMSO
or meridianin C‐treated cells were fixed overnight at 4°C with 2.5%
glutaraldehyde in 0.1 M sodium cacodylate buffer, pH 7.4. Samples
were post‐fixed for 30 min with 0.5% osmium tetroxide/0.8% potas-
sium ferricyanide, transferred to 1% tannic acid for 1 h and then to
1% uranyl acetate overnight at 4°C. Next, the samples were dehy-
drated with a graded ethanol series and embedded in Spurr's resin.
Thin sections were cut with a Leica EM UC6 ultramicrotome (Leica),
and stained with 1% uranyl acetate and Reynold's lead citrate prior
to viewing at 120 kV on a Tecnai BT Spirit transmission electron
microscope (FEI). Digital images were acquired with a Hammamatsu
XR‐100 side mount digital camera system (Advanced Microscopy
Techniques) and processed using Adobe Photoshop CS5 (Adobe Sys-
tems Inc.).
2.4 | Scanning electron microscopy
YD‐10B cells were seeded in 6‐well plates (0.5 × 106 cells/2 mL/
well) the day before meridianin C treatment. Cells were then
treated with vehicle control (DMSO) or 1 μM meridianin C for 2 h.
The conditioned cells were centrifuged, fixed in 0.5% glutaralde-
hyde and 0.5% paraformaldehyde fixative, washed with 0.1 M
phosphate‐buffered saline (PBS), and post‐fixed with 1% osmium
tetroxide solution for 1 h. 2% tannic acid was used to conductively
stain for 12 h, later washed with PBS, and fixed with 1% osmium
tetroxide solution for 1 h. The specimens were dehydrated with
ethanol, t‐butyl alcohol and freeze dryer. Finally, the specimen was
sputter coated with platinum‐palladium (Pt‐Pd) in an ion coater for
2 min, followed by microscopic examinations (S‐4200, Hitachi Co.,
Tokyo, Japan).
2.5 | Measurement of DNA fragmentation
YD‐10B cells were seeded in 6‐well plates at a density of 0.5 × 106
cells per well the day before treatment. Cells were incubated with
meridianin C or vehicle control (DMSO) for 4 to 48 h, at which
point, cells were harvested, washed and lysed in a buffer containing
50 mM Tris (pH 8.0), 0.5% sarkosyl, 0.5 mg/mL proteinase K and
1 mM EDTA at 55°C for 3 h, followed by addition of RNase A
(0.5 μg/mL) for a further 18 h at 55°C. The lysates were then cen-
trifuged at 10 000 g for 20 min, genomic DNA in the supernatant
was extracted with equal volume of neutral phenol–chloroform–isoa-
myl alcohol mixture (25:24:1), and analysed by electrophoresis on a
1.7% agarose gel. The DNA was visualized and photographed under
UV illumination after staining with ethidium bromide (0.1 μg/mL).
2.6 | Measurement of the population of sub G1
phase by flow cytometry analysis
After 24‐ or 48‐h treatment with DMSO or meridianin C (1 μM), YD‐
10 B cells were harvested and washed with PBS, fixed in ice‐cold
70% ethanol and stored at 4°C. Cells were then washed once with
PBS, suspended in 1 mL of cold propidium iodide (PI) solution con-
taining 100 μg/mL RNase A, 50 μg/mL propidium iodide, 0.1% (w/v)
sodium citrate and 0.1% (v/v) NP‐40 and incubated on ice for addi-
tional 30 min in the darkness. Cytometric analyses were carried out
with a flow cytometer (FACS Caliber, Becton Dikinson) and
CellQuest software. Approximately, 10 000 cells were counted for
the analysis.
2.7 | Fluorescein isothiocyanate (FITC) staining
To monitor the functionality of meridianin C‐induced macropinocyto-
sis (macropinosome formation/internalization), 0.25 × 105 YD‐10B
cells/mL were seeded on coverslips and treated with meridianin C
(1 μM) and/or FITC‐dextran (0.5 mg/mL) in the presence or absence
of amiloride (4 mM) for 4 h. The cells were washed twice with PBS
and mounted onto microscopic glass slides using Permafluor aqueous
mounting media (Thermo Scientific, Waltham, MA, USA) media.
Bright field and fluorescence were observed using a Zeiss AxioOb-
server.A1 inverted microscope (Carl Zeiss, Germany) and images
acquired using Zen 2 software (Carl Zeiss). Fluorescent intensity was
quantified using Image‐J software.
2.8 | Preparation of whole cell lysates
To see the effect of meridianin C on expression of apoptosis‐ or
macropinocytosis‐related proteins, YD‐10B cells (0.5 × 106/2 mL/
well) were seeded in 6‐well plates the day before meridianin C treat-
ment. Cells were treated with meridianin C (1 μM) or vehicle control
(DMSO) for the indicated times. At each time‐point, cells were
washed twice with PBS and proteins extracted using a modified
RIPA buffer (50 mM Tris‐Cl (pH 7.4), 150 mM NaCl, 0.1% sodium
dodecyl sulphate, 0.25% sodium deoxycholate, 1% Triton X‐100, 1%
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Nonidet P‐40, 1 mM EDTA, 1 mM EGTA, PIC (1×)). The cell lysates
were collected and centrifuged at 12 000 rpm for 20 min at 4°C.
The supernatants were saved and protein concentrations determined
by bicinchoninic acid assay (BCA) protein assay (Pierce).
2.9 | Immunoblot analysis
Proteins (50 μg) were separated by SDS‐PAGE (10%) and transferred
onto nitrocellulose membranes (Millipore, Bedford, MA, USA). The
membranes were washed with TBS (10 mM Tris‐Cl, 150 mM NaCl,
pH 7.5) with 0.05% (v/v) Tween‐20 followed by blocking with TBST
containing 5% (w/v) non‐fat dried milk. The membranes were incu-
bated overnight with antibodies specific for procaspase‐9 (1:1000),
DR‐5 (1:1000), PARP (1:2000), DKK‐3 (1:1000), Flag (1:1000) or β‐
actin (1:10 000) at 4°C. The membranes were then exposed to sec-
ondary antibodies conjugated to horseradish peroxidase for 2 h at
room temperature and further washed three times with TBST.
Immunoreactivity was detected by SuperSignal™ West Pico PLUS
enhanced chemiluminescence (ECL) according to manufacturer
(Thermo Scientific, Waltham, MA, USA). Equal protein loading was
assessed by the expression levels of β‐actin.
2.10 | Small interfering RNA (siRNA) transfection
YD‐10B cells (0.5 × 105/well) seeded into 6‐well plates were trans-
fected for 6 h with control or DKK‐3 siRNA (80 pM) using Lipofec-
tamineTM 2000 (Invitrogen, Carlsbad, CA, USA). Culture medium
from the transfected cells was removed and refreshed with RPMI
containing 10% FBS, followed by incubation for 18 h. The knock-
down efficiency of the DKK‐3 siRNA was determined by
immunoblotting in comparison to β‐actin.
2.11 | Generation of stable YD‐10B cells
overexpressing DKK‐3
The pcDNA3.1‐DKK3‐C‐Flag or mock vector was constructed as
reported previously.27 Briefly, YD‐10B cells were transfected in a
stable manner with the pcDNA3.1‐DKK‐3‐Flag or mock vector using
LipofectAMINE transfection reagent as prescribed by the manufac-
turer (Invitrogen, Carlsbad, CA, USA). After 48 h of incubation, trans-
fected cells were selected in primary cell culture medium containing
200 μg/mL G418 (Promega, Madison, WI, USA). After 2 or 3 weeks,
to rule out the possibility of clonal differences between the gener-
ated stable cell lines, the pooled YD‐10B/mock vector and YD‐10B/
DKK‐3‐Flag clones were tested for DKK‐3 and Flag expression by
immunoblotting and were used in this study.
2.12 | Statistical analyses
Cell count analysis was performed in triplicates and repeated three
times. Data were expressed as mean ± SEM. The significance of dif-
ference was determined by one‐way ANOVA (Laerd Statistics, Chi-
cago, IL, USA). All significance testing was based upon a P < 0.05.
3 | RESULTS
3.1 | Meridianin C has strong growth inhibitory and
vacuole‐inducing effects on YD‐10B cells
We investigated the treatment effect of meridianin C (Figure 1A) at
1 μM concentration for 48 h on the growth of four different human
tongue carcinoma cell lines (YD‐8, YD‐10B, YD‐38 and HSC‐3) by
cell count analysis. Among the cell lines tested, YD‐10B cells were
the most sensitive to meridianin C (Figure 1B). Meridianin C treat-
ment led to a slight reduction in HSC‐3 cells, which was statically
insignificant. Both YD‐38 and YD‐8 and cells were insensitive to
meridianin C treatment. Strikingly, YD‐10B cells treated with meridi-
anin C were highly vacuolated (Figure 1C). Furthermore, HSC‐3 cells
treated with meridianin C also formed many vacuoles in much smal-
ler size than those in YD‐10B cells. However, both YD‐38 and YD‐
8 cells treated with meridianin C had very low or no cytoplasmic
vacuoles. Meridianin C caused a time‐dependent increase in cyto-
plasmic vacuole formation in YD‐10B cells, with effects visible by
2 h (Figure 1D). We next examined the effect of meridianin C on
growth and accumulation of vacuoles in normal human gingival
fibroblast (HGF), but no cytoplasmic vacuoles were observed at 4,
8, 24 or 48 h, and meridianin C was not cytotoxic to HGF (Fig-
ure 1E). However, it was shown that treatment with meridianin C
at higher concentrations (5 or 10 μM) and different times (2, 4, 8,
24 or 48 h) strongly reduced survival and induced massive vacuoles
of both YD‐10B and normal HGFs, pointing out that meridianin C
at higher concentrations (5 or 10 μM) than 1 μM are cytotoxic to
YD‐10B cells as well as normal HGFs. These results show that
meridianin C has a strong and selective anti‐survival and vacuole‐
inducing effects on the highly invasive and tumorigenic YD‐10B
cells at the 1 μM concentration. Therefore, we decided to focus on
the YD‐10B cell line and the 1 μM concentration of meridianin C
for further studies.
F IGURE 1 Meridianin C inhibits YD‐10B cell survival and induces cellular vacuole formation. (A) The chemical structure of meridianin C. (B)
Four human tongue cancer cell lines (YD‐8, YD‐10B,YD‐38, and HSC‐3), respectively, were treated with meridianin C (1 μM) or vehicle control
(DMSO; 0.1%) for 48 h. The number of surviving cells was measured by trypan blue dye exclusion. Data are mean ± SEM of three independent
experiments, each done in triplicate. *P < 0.05 compared to the value of meridianin C free control at the indicated time. (C) YD‐8, YD‐10B, YD‐
38 and HSC‐3 cells, respectively, were treated with meridianin C (1 μM) or vehicle control (DMSO) for 48 h. Images of the conditioned cells
were obtained by phase contrast microscopy, 400 X. Each image is a representative of three independent experiments. (D, E) YD‐10B cells or
normal human gingival fibroblasts (HGF) were treated with meridianin C (1 μM) or vehicle control (DMSO) for the times indicated. At each time‐
point, images were obtained by phase contrast microscopy, 400 X. Each image is a representative of three independent experiments
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3.2 | Meridianin C does not induce apoptosis in
YD‐10B cells
We next determined whether meridianin C treatment induces apop-
tosis in YD‐10B cells by nuclear DNA fragmentation assay. As shown
in Figure 2A, no apoptotic DNA fragmentation occurred in YD‐10B
cells when treated with meridianin C for 4, 8, 24 or 48 h. Further to
confirm apoptosis, we analysed the amount of subG1 DNA by flow
cytometry in YD‐10B cells treated with 1 μM meridianin C for the
indicated times (24, 48 h). As shown in Figure 2B, the addition of
meridianin C did not result in increased accumulation of sub‐G1
phase, a well‐known apoptotic marker. Further, Western blotting
analysis revealed that meridianin C treatment did not affect expres-
sion levels of apoptosis‐related proteins, procaspase‐9 and death
receptor‐5 (DR‐5), or PARP cleavage (Figure 2C) until 48 h of treat-
ment. Moreover, treatment with z‐VAD‐fmk, a pan‐caspase inhibitor
28 did not block the meridianin C‐induced growth inhibition and
accumulation of vacuoles in YD‐10B cells (Figure 2D, E).
3.3 | Meridianin C induces macropinocytosis
(macropinosomes) in YD‐10B cells
Using transmission electron microscopy (TEM), we investigated
whether vacuoles induced by meridianin C in YD‐10B cells are
macropinosomes. While YD‐10B cells treated with vehicle control
(DMSO) had no or tiny vacuoles in the cytoplasm (Figure 3A), the
meridianin C‐treated cells displayed ultrastructural characteristics of
macropinosomes (vacuoles) in different sizes (arrows) (Figure 3B).
Under high magnification, the meridianin C‐treated YD‐10B cells
showed fusion between large and small vacuoles in the cytoplasm
(arrows) and indentation of the nuclear membrane (arrowhead) prob-
ably because of enlarged vacuolar structure (Figure 3C). Further-
more, residual materials, including membranous debris (arrowheads),
were seen within the cytoplasmic vacuoles (arrows) in YD‐10B cells
treated with meridianin C (Figure 3D). It is documented that macro-
pinosomes are derived from membrane ruffles and protrusions fold-
ing back and fusing with the plasma membrane to form large
F IGURE 2 Meridianin C does not induce apoptosis of YD‐10B cells. (A) YD‐10B cells were treated with meridianin C (1 μM) or vehicle control
(DMSO) for the times indicated. At each time‐point, extra‐nuclear fragmented DNA was extracted, and analysed on a 1.7% agarose gel. The
images are representative of three independent experiments. SM, DNA size marker. (B) YD‐10B cells were treated with meridianin C (1 μM) or
vehicle control (DMSO) for the times indicated and evaluated for apoptotic subG1 DNA content by flow cytometer. The tables represent the
fraction of apoptotic cells. Data are mean ± SEM of three independent experiments. (C) YD‐10B cells were treated with meridianin C (1 μM) or
vehicle control (DMSO) for the times designated. At each time‐point, whole cell lysates were prepared, and analysed for procaspase‐9, DR5, PARP
cleavage and β‐actin by Western blotting. The images are representative of three independent experiments. (D) YD‐10B cells were treated with
meridianin C (1 μM) in the absence or presence of z‐VAD (50 μM), a pan‐caspase inhibitor, for 48 h, and cell survival counted by the trypan blue
dye exclusion assay. Data are mean ± SEM of three independent experiments, each performed in triplicate. *P < 0.05 compared to the control at
the indicated time. (E) YD‐10B cells were treated with meridianin C (1 μM) in the absence or presence of z‐VAD (50 μM), a pan‐caspase inhibitor,
for 48 h. Images were obtained by phase contrast microscopy, 400 X. Each image is representative of three independent experiments
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vesicles.29 Further, to confirm that the formation of macropinosomes
induced by meridianin C is the result of macropinocytosis, scanning
electron microscopy (SEM) was used to see the effect of meridianin
C on induction of membrane ruffling or lamellipodia formation in
YD‐10B cells. Apparently, while vehicle control (DMSO)‐treated YD‐
10B cells had many short and thick bacilli bound to the cell surface
(thin arrows) (Figure 3E), there were abundant long and thin mem-
brane extensions that resemble lamellipodia (wide white arrows) on
the surface of cells treated with meridianin C for 2 h (Figure 3F).
3.4 | Meridianin C‐induced macropinocytosis
(macropinosome formation/internalization) in YD‐10B
cells is functional
Amiloride inhibits macropinocytosis by blocking the activity of Na/H
exchanger, causing a decrease in pH at the plasma membrane.30 This
amiloride‐induced pH drop suppresses the membrane ruffling and
membrane extensions that form the macropinosome.31 Soluble
sugars or proteins, such as dextran or albumin, are useful fluorescent
markers specific for macropinocytosis.32 Using amiloride and fluores-
cein isothiocyanate‐dextran with molecular weight of 70 kDa (FITC‐
dextran), we sought to explore whether the meridianin C‐induced
macropinocytosis (macropinosome formation/internalization) in YD‐
10B cells is functional. Microscopic observations clearly demon-
strated that amiloride strongly blocked the meridianin C‐induced
accumulation of vacuoles in YD‐10B cells (Figure 4A). Moreover,
meridianin C increased the delivery of FITC‐dextran into YD‐10B
cells while amiloride strongly inhibited it (Figure 4B). Further, fluo-
rescence intensity of FITC‐dextran (green colour) was determined by
Image‐J software (Figure 4C).
3.5 | Meridianin C‐induced down‐regulation of
DKK‐3 protein in YD‐10B cells
DKK‐3 plays a role in modulating macropinocytosis in T24 human
bladder cancer cells 16 and is also expressed in OSCC‐derived cell
A B
C D
E F
F IGURE 3 Transmission and scanning
electron micrographs of meridianin C‐
induced macropinosomes and
macropinocytosis in YD‐10B cells. (A‐D)
YD‐10B cells were treated with meridianin
C (1 μM) or vehicle control (DMSO) for 8
h. (A) Vehicle (DMSO)‐treated cells, 2000
X. (B) Meridianin C‐treated cells, 2000 X.
Arrows indicate the cytoplasmic vacuoles
of different sizes. (C) Meridianin C‐treated
cells, 4000 X. Arrowhead indicates the
indented or distorted nucleus because of
enlarged vacuole. Arrows indicate fusion
between cytoplasmic vacuoles of different
sizes. (D) Meridianin C‐treated cells, 5000
X. Arrows indicate macropinosomes
containing membranous contents in
different sizes, which are shown by
arrowheads. (E, F) YD‐10B cells were
treated with meridianin C (1 μM) or vehicle
control (DMSO) for 2 h. (E) Vehicle control
treated cells, which show many short and
thick bacilli bound to the cell surface (thin
arrows). (F) Meridianin C‐treated cells,
which exhibit abundant long and thin
membrane extensions that resemble
lamellipodia on the cells surface (wide
white arrows)
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lines.33 We therefore sought to explore whether DKK‐3 is expressed
in YD‐10B cells and is regulated by meridianin C treatment. As
shown in Figure 5A, high cellular levels of DKK‐3 protein were seen
in YD‐10B cells, and its expression level was even higher relative to
β‐actin than that in T24 cells. There was no detectable DKK‐3
protein expression in YD‐8 or YD‐38 cells. Time course experiments
further revealed that meridianin C treatment led to a rapid
time‐dependent reduction in DKK‐3 protein in YD‐10B cells
(Figure 5B‐D).
3.6 | DKK‐3 knock‐down led to partial
accumulation of vacuoles in YD‐10B cells along with
partial decrease of the cell growth
To evaluate the role of reduced DKK‐3 in meridianin C's growth inhi-
bition and/or macropinocytosis in YD‐10B cells, we transfected con-
trol or DKK‐3 siRNA into YD‐10B cells and measured the number of
surviving cells and accumulation of cytoplasmic vacuoles. There was
almost complete knock‐down of DKK‐3 in the DKK‐3 siRNA‐trans-
fected YD‐10B cells, compared with the control siRNA‐transfected
ones (Figure 6A), suggesting high DKK‐3 siRNA transfection effi-
ciency. YD‐10B cells transfected with DKK‐3 siRNA had partial accu-
mulation of vacuoles (Figure 6B) accompanied with a partial but
significant reduction in cell survival (Figure 6C).
3.7 | Overexpression of DKK‐3 largely blocks
meridianin C‐induced accumulation of vacuoles in
YD‐10B cells along with significant increase of the
cell survival
To further clarify that DKK‐3 plays an important role in the function
of meridianin C, we next performed DKK‐3‐Flag cDNA transfection
experiments to generate stable YD‐10B cells that overexpress DKK‐3‐
Flag. Using these stable clones, we tested whether DKK‐3 overexpres-
sion could interfere with the meridianin C's growth inhibitory and vac-
uole‐inducing activities in YD‐10B cells. As shown in Figure 7A, there
was a large increase in DKK‐3 protein levels in YD‐10BDKK-3 cells (cells
overexpressing DKK‐3‐Flag) compared with YD‐10Bmock cells (cells
transfected with mock vector). High levels of Flag expression in YD‐
10BDKK-3, but not in YD‐10Bmock, cells further support the DKK‐3
cDNA transfection efficiency. As expected, meridianin C led to a
decrease in DKK‐3 protein levels in YD‐10Bmock cells. However,
meridianin C did not influence DKK‐3 protein expression in YD‐
10BDKK-3 cells, although it slightly reduced Flag levels in the cells.
Importantly, while meridianin C treatment largely induced many vac-
uoles in YD‐10Bmock cells, it had no effect on the formation of vac-
uoles in YD‐10BDKK-3 cells (Figure 7B). Furthermore, as shown in
Figure 7C, the meridianin C‐induced reduction in YD‐10B cell survival
was considerably blocked by DKK‐3 overexpression.
F IGURE 4 Suppression of meridianin C‐
induced macropinocytosis
(macropinosomes) in YD‐10B cells by
amiloride, a macropinocytosis inhibitor. (A)
YD‐10B cells were treated with meridianin
C (1 μM) in the absence or presence of
amiloride (4 mM) for 4 h. Images were
obtained by phase contrast microscopy,
400 X. Each image is a representative of
three independent experiments. (B) YD‐
10B cells were seeded on coverslips and
treated with meridianin C (1 μM) and/or
FITC‐dextran (0.5 mg/ml) in the absence or
presence of amiloride (4 mM) for 4 h. The
cells were washed and mounted onto
microscopic glass slides. Bright field and
fluorescence were observed with a Zeiss
AxioObserver.A1 inverted microscope and
images were acquired using Zen 2
software. (C) Fluorescence intensity of
FITC‐dextran (green colour) was
determined by Image‐J software. Each
value in the graph represents the
mean ± SEM of three independent
experiments. *P < 0.05 compared to the
meridian C treatment at the indicated time
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3.8 | The meridianin C's growth inhibitory and
macropinocytosis inducing effects on YD‐10B cells
are reversible
To determine whether meridianin C exerts its effects on YD‐10B cell
survival and macropinocytosis in a reversible or irreversible manner,
YD‐10B cells were incubated with meridianin C or DMSO solvent
control at the designated time‐points, as illustrated in Figure 8A. YD‐
10B cells that were incubated with vehicle DMSO control for 4 h
and then incubated with DMSO vehicle for an additional 1, 2, 4 and
20 h, showed no vacuole formation (treatment a) (Figure 8B). In con-
trast, YD‐10B cells that were incubated with meridianin C for 4 h
and then further incubated with meridianin C for an additional 1, 2,
4 and 20 h, respectively, showed many vacuoles (treatment b). How-
ever, YD‐10B cells that were incubated with meridianin C for 4 h
and then incubated with DMSO vehicle control for an additional 1,
2, 4 and 20 h, respectively, showed a time‐dependent reduction in
vacuole number (treatment c). Importantly, the survival of YD‐10B
cells in treatment c was much higher than that of the cells in treat-
ment b (Figure 8C). These results show that the growth inhibitory
and macropinocytosis inducing effects of meridianin C on YD‐10B
cells do occur in a reversible manner.
3.9 | Comparison of the effects of meridianin C and
its derivatives on growth and macropinosome
(vacuole) accumulation in YD‐10B cells
We have recently synthesized a novel series of meridianin C deriva-
tives substituted at C‐5 position (7a‐j) and reported their anti‐
F IGURE 5 Effect of meridianin C on expression of DKK‐3 in YD‐
10B cells. (A) Whole cell lysates of YD‐8, YD‐10B, YD‐38 or T24 cells
were analysed for DKK‐3 or β‐actin by Western blotting. (B) YD‐10B
cells were treated with meridianin C (1 μM) or vehicle control (DMSO)
for the times designated or (C) for 20 min. At each time‐point, whole
cell lysates were prepared, and analysed for DKK‐3 compared to β‐
actin by Western blotting. (D) The densitometry data of (C). *P < 0.05
compared to the control (−) at the indicated time
F IGURE 6 Effects of DKK‐3 knockdown on accumulation of
vacuoles and growth of YD‐10B cells. (A) YD‐10B cells were
transfected with 80 pM of control or DKK‐3 siRNA for 24 h. Whole
cell lysates were prepared, and analysed by Western blot. The pictures
are representative of three independent experiments. (B) YD‐10B cells
were transfected with 80 pM of control or DKK‐3 siRNA for 24 h.
Images were obtained by phase contrast microscopy, 400 X. Each
image is representative of three independent experiments. (C) YD‐10B
cells were transfected with 80 pM of control or DKK‐3 siRNA for
24 h, and cell survival counted by the trypan blue dye exclusion assay.
Data are mean ± SEM of three independent experiments, each
performed in triplicate. *P < 0.05 compared to the value of control
siRNA at the indicated time
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proliferative activities against human leukaemic cell lines.23 In this
study, we tested these meridianin C derivatives on growth and
macropinosome (vacuole) accumulation of YD‐10B cells. Meridianin
C treatment for 48 h strongly inhibited the survival of YD‐10B cells
(Figure 9A). However, treatment with 7a, 7b, 7c, 7f, 7e, 7 h or 7i
only slightly decreased of the cell survival. Treatment with 7d, 7 g or
7j had no effect on the survival of YD‐10B cells. Similarly, meridianin
C treatment induced a significant accumulation of vacuoles in YD‐
10B cells, whereas compounds 7a‐j had no or very low vacuole‐indu-
cing activity (Figure 9B).
4 | DISCUSSION
Macropinocytosis can be activated and exploited in normal and
cancer cells to confer a cell growth/survival advantage.34–36 By con-
trast, hyper‐stimulation of macropinocytosis might play a critical
role in the cytotoxicity of normal and cancer cells.35,37 Notably,
there are a number of several natural or synthetic chemicals that
have anti‐tumour effects through stimulation of macropinocyto-
sis.38,39 Indeed, it has been suggested that any substance that
specifically and massively induces macropinocytosis in cancer cells
may have therapeutic potential as an anti‐tumour agent. Regulation
of human tongue cancer cell growth and macropinocytosis by
meridianin C has not been reported previously. In this study, we
demonstrate that meridianin C has strong growth suppressive and
macropinocytosis inducing effects on YD‐10B human tongue cancer
cells and the effects are mediated in part through regulation of
DKK‐3 expression.
Aforementioned, meridianin C, D or G analogues/derivatives are
anti‐proliferative in several types of human cancer cells, including
breast (MCF‐7), cervix (HeLa) and leukaemia (MV4‐11).21–23 Here we
initially screened four different human tongue cancer cell lines (YD‐
8, YD‐10B, YD‐38 and HSC‐3) to see whether meridianin C treat-
ment affects the cell survival. We found that meridianin C strongly
and specifically reduced the survival of YD‐10B cells. However, the
apoptotic parameters, including nuclear DNA fragmentation, popula-
tion of sub G1, expression of procaspase‐9 (no expression of cleaved
and active form of caspase‐9) and PARP cleavage, did not indicate
apoptosis as the mechanism of action of meridianin C. Moreover,
the microscopic and TEM analyses in this study showed that meridi-
anin C rapidly induced cytoplasmic vacuoles/macropinosomes in YD‐
10B cells. The SEM analysis further demonstrated, the ability of mer-
idianin C to rapidly induce abundant long and thin membrane exten-
sions that resemble lamellipodia on the surface of YD-10B cells.
These results strongly support the notion that the formation of
macropinosomes induced by meridianin C in YD‐10B cells is the
result of macropinocytosis. Meridianin C has previously been
reported to inhibit Pim‐1, CDK‐1, CDK‐5, PKA, PKG, GSK‐3β and
CK‐1 activity with IC50 values of 1.4, 3, 6, 0.7, 0.4, 2 and 30 μM,
respectively.23,40 There are no reports showing a relationship
between cell survival or macropinocytosis induction and those
F IGURE 7 Effects of DKK‐3 overexpression on meridianin C‐induced accumulation of vacuoles and decrease in survival of YD‐10B cells. (A)
YD‐10B cells were transfected with pcDNA3.1‐DKK‐3‐Flag or mock vector using LipofectAMINE 2000 reagents. Stable clones were selected in
the culture media containing 200 μg/ml G418 sulphate for several weeks. The selected clones (DKK‐3‐Flag or mock vector‐transfected YD‐10B
cells) were seeded overnight. Cells were then treated with or without meridianin C (1 μM) for 20 min. Cell lysates were prepared and analysed
by Western blotting for measurement of the expression levels of DKK‐3, Flag and β‐actin. (B) DKK‐3‐ or mock‐transfected YD‐10B cells were
treated vehicle or meridianin C (1 μM) for 4 h. Images were obtained by phase contrast microscopy, 400 X. Each image is a representative of
three independent experiments. (C) DKK‐3‐ or mock‐transfected YD‐10B cells were treated with or without meridianin C (1 μM) for 24 h,
followed measurement of the number of cells survived by the trypan blue dye exclusion assay. Data are mean ± SEM of three independent
experiments, each performed in triplicate. *P < 0.05 compared to the control at the indicated time
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kinases in cancer cells including YD‐10B cells. However, one can
speculate that meridianin C's growth inhibitory and/or macropinocy-
tosis inducing effects on YD‐10B cells may be through acting upon
one or more of these kinases, which yet remain to be elucidated.
A notable finding of the present study is meridianin C regula-
tion of DKK‐3 expression in YD‐10B cells. DKK‐3 is one of the
DKK protein families and is known as a Wnt antagonist.41,42 It is
also recognized as a potential tumour suppressor, based on the
facts that DKK‐3 expression is frequently down‐regulated in a
wide array of malignancies.43,44 Recent evidence indicates that
DKK‐3 may also play additional roles in cancer cell survival. DKK‐
3 knock‐down by siRNA in T24 human bladder cancer cells inhib-
ited cell growth and induced macropinocytosis and autophagy.16 It
also has been recently demonstrated that DKK‐3 is expressed in a
subset of OSCC‐derived cell lines including HSC‐4.33 Moreover, in
HSC‐4 cells, DKK‐3 knock‐down inhibited migration and invasion.
These results imply that DKK‐3 may have a metastasis‐related
oncogenic function in OSCC. Here we found DKK‐3 is highly
expressed in YD‐10B cells and meridianin C suppresses its expres-
sion. To the best of our knowledge, this is the first study showing
the ability of meridianin C to down‐regulate DKK‐3 in cancer cells.
Of further importance, the present study revealed that siRNA‐
based gene silencing of endogenous DKK‐3 led to partial accumu-
lation of vacuoles in YD‐10B cells along with partial inhibition of
the cell survival. Moreover, we herein have demonstrated that
overexpression of DKK‐3 blocks the marcopinocytosis inducing
property of meridianin C and leads to increase in cell survival
against meridianin C treatment. Altogether, these findings show
that DKK‐3 may have a role in controlling survival and
macropinocytosis in YD‐10B cells and this is inhibited by
meridianin C.
The reversibility of cancer cell growth inhibition after drug removal
has clinical implications. In this study, we further evaluated the effects
of meridianin C withdrawal on cell survival and macropinocytosis in
YD‐10B cells. We found that meridianin C's anti‐survival and
macropinocytosis inducing effects on YD‐10B cells were reversible.
Several reports have recently described that hyper‐stimulation of
macropinocytosis and/or disruption of normal macropinosome matura-
tion associated with abnormal/massive accumulation of intracellular
vacuoles leads to the cytotoxicity and/or nonapoptotic cell death of
cancer cells.45–47 We would similarly speculate that the anti‐survival
effect of meridianin C on YD‐10B cells is closely linked to this drug‐
induced rapid and sustained accumulation of macropinosomes in the
cells. We have similarly found that meridianin C can induce
macropinocytosis (macropinosomes) in HSC‐3 cells, another human
tongue cancer cell line, indicating that the meridianin C's macropinocy-
tosis effects are not limited to YD‐10B cells. Further characterization
of meridianin C's responses in YD‐10B cells compared to YD‐8 and
F IGURE 8 Reversibility of the
meridianin C's actions on macropinocytosis
and cell survival in YD‐10B cells. (A)
Schematic outline of the experimental
setup: The double‐headed arrows indicate
the length of meridianin C (1 μM)
treatment. (B) YD‐10B cells were treated
with meridianin C (1 μM) or vehicle control
(DMSO) for the indicated time periods. At
each time‐point, images were obtained by
phase contrast microscopy, 400 X. Each
image is representative of three
independent experiments. (C) YD‐10B cells
were treated with meridianin C (1 μM) or
vehicle control (DMSO) for the indicated
time periods, and the cell count assay
performed in triplicate. Data are
mean ± SEM of three independent
experiments. *P < 0.05 compared to the
control at the indicated time. #P < 0.05
compared to the value of meridianin C at
the indicated time‐point
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YD‐38 cells, which are unresponsive to meridianin C, may further help
to elucidate its mechanism of action.
We have recently synthesized a series of meridianin C deriva-
tives, and demonstrated their anti‐proliferative activity in human leu-
kaemia cell lines including MV4‐11.23 In the current study, we
further compared the growth inhibitory and/or macropinocytosis
inducing effects of meridianin C and its derivatives on YD‐10B cells.
Although some of meridianin C derivatives had macropinocytosis
inducing and growth inhibitory effects on YD‐10 cells, it was evident
that their effects were much weaker than those induced by its par-
ental compound meridianin C. These results indicate that meridianin
C has a unique structural moiety leading to strong growth suppres-
sive and macropinocytosis inducing activity in YD‐10B cells, which is
distinct from other cancer cells.
In summary, meridianin C induces a significant level of
macropinocytosis and selectively decreases the survival of YD‐10B
cells in part through a reduction in DKK‐3. Although there are still
important issues that remain to be resolved, including meridianin C's
macropinocytosis inducing and anti‐tumour effects on animal models,
our findings suggest that meridianin C is a potential novel target for
metastatic human tongue cancer.
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